SEC Form 4 · accession 0001394548-17-000025
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Ashton
Director
Period of report
Jun 28, 2017
Accepted (ET)
Jul 6, 2017 · 5:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 6, 2017 | A | 9,866 | $0.59 | A | 22,682 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F4 | $0.55 | Jun 8, 2017 | A | 5,000 | A | — | Jun 8, 2027 | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter.
- F2Represents the closing stock price of the Company's stock on the first trading day of the quarter.
- F3Granted pursuant to the Issuer's 2016 Incentive Plan.
- F4This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018.